← Back to Search

Cannabinoid

Low dose RLS103 for Social Anxiety Disorder

Phase 1

Waitlist Available

Research Sponsored by Receptor Life Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 minutes, assessed at visit 2 and visit 3

Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help people with social anxiety disorder during a public speaking challenge.

Eligible Conditions

Social Anxiety Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 minutes, assessed at visit 2 and visit 3

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 minutes, assessed at visit 2 and visit 3

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 minutes, assessed at visit 2 and visit 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence and severity of adverse events

Secondary outcome measures

Change in CGI

Change in subject-reported anxiety

Other outcome measures

Changes in blood pressure in subjects with SAD

Changes in pulse rate in subjects with SAD

Changes in respiratory rate in subjects with SAD

Trial Design

3Treatment groups

Experimental Treatment

Group I: placeboExperimental Treatment1 Intervention

placebo inhaled dry powder

Group II: Low dose RLS103Experimental Treatment1 Intervention

3 mg CBD inhaled dry powder

Group III: High dose RLS103Experimental Treatment1 Intervention

6 mg CBD inhaled dry powder

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Receptor Life SciencesLead Sponsor

1 Previous Clinical Trials

2 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks do individuals face when using Low dose RLS103?

"Low dose RLS103 has limited evidence for both safety and efficacy, so it was given a rating of 1."

Answered by AI

How many participants are enrolled in this clinical experiment?

"Affirmative. According to clinicaltrials.gov, the medical trial initiated on May 18th 2022 is still in a period of recruitment and requires 30 participants from 3 distinct locations."

Answered by AI

Is this research endeavor currently recruiting participants?

"That is correct. Clinicaltrials.gov reports that this clinical trial, which was initiated on May 18th 2022, requires 30 participants at 3 different medical centres and is still actively recruiting patients."

Answered by AI

Is this research seeking to include participants that are over 40 years old?

"This study requires that potential participants be aged between 18 and 65. In addition, there are 111 clinical trials available for minors and 274 specifically catering to patients over the age of retirement."

Answered by AI

What are the criteria to be eligible for participation in this trial?

"This medical trial is recruiting 30 participants aged 18-65 who suffer from anxiety disorders. In order to be considered for enrollment, potential study members must sign an ICF (Informed Consent Form) and abide by a range of other criteria including being non-smokers with no nicotine use in the prior month, having a LSAS total score ≥75 and HAM-D 17 Score <18 at Screening, BMI between 18 - 32 kg/m2 and weight over 50kg, negative viral serology test results HIV1/HIV2 HBV HCV , female subjects of childbearing capacity must commit to effective contraception during trial duration"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

2022. "Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05429788.